IRONWOOD PHARMACEUTICALS INC 8-K

What Happened
Ironwood Pharmaceuticals, Inc. (IRWD) filed an 8-K reporting that Senior Vice President & Chief Financial Officer Gregory Martini notified the company on May 8, 2026 that he will resign effective May 15, 2026. The filing states his resignation is not due to any disagreement with the company on financial reporting matters. Effective May 15, 2026, Ronald Silver, the company’s Senior Vice President, Corporate Controller and Chief Accounting Officer, will serve as interim chief financial officer and principal financial officer.

Key Details

• Resignation notice: Gregory Martini notified the company on May 8, 2026; resignation effective May 15, 2026.
• Interim appointment: Ronald Silver named interim CFO/principal financial officer effective May 15, 2026.
• Mr. Silver background: joined Ironwood in June 2018; served as SVP, Corporate Controller & Chief Accounting Officer since January 2025; previously held controller and accounting roles at Ironwood and roles at Eze Software Group and RSM. He is a CPA with a B.S. in accounting (University of Maryland) and an MBA (Georgetown).
• Disclosures: No disagreement with management on financial reporting was cited; no special arrangements for Mr. Silver’s selection; no family relationships or reportable related-party transactions involving Mr. Silver since Jan 1, 2024.

Why It Matters
A CFO transition is material because the principal financial officer leads financial reporting and investor communications. Ironwood appointed an internal, experienced accounting executive as interim CFO, which may support continuity in financial controls and reporting. The filing’s statement that the resignation is not due to a disagreement on financial reporting and the absence of related-party issues for the interim CFO are governance details investors monitor for transparency and stability.